Back to search

Article

IFNA pathway drives the more aggressive phenotype of <i>KRAS</i> <sup>G12D</sup> -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

2022-07-01

Abstract excerpt

Activating mutations of KRAS play critical roles in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Accumulating evidence indicates that distinct KRAS alleles associate with different prognoses, but the underlying mechanisms are not known. We established isogenic KRAS mutants ( KRAS G12D , KRAS G12V , and KRAS WT ) using a KRAS G12R patient-derived PDAC cell line by CRISPR/Cas9 kn...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3ddaa4c9-e8be-556f-958b-4aa02c9ad29e
DOI
10.1101/2022.06.29.497540
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
IFNA pathway drives the more aggressive phenotype of <i>KRAS</i> <sup>G12D</sup> -mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activationDOI 10.1101/2022.06.29.497540
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity
KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity
SMAD4 and KRAS status shape malignant-stromal crosstalk in pancreatic cancerSemantic proximity
A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.Semantic proximity
Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity
Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with <i>KRAS-TP53</i> Co-Alteration in Pancreatic CancerSemantic proximity
Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesisSemantic proximity
Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity
Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity
Select a neighboring publication to make it the new centre.